According to reports, in 2020, online searches for chin enhancement products, like Restylane Defyne, increased by 185%.
Galderma recently announced that the U.S. Food and Drug Administration (FDA) has approved Restylane Defyne for the augmentation and correction of mild to moderate chin retrusion for adults over the age of 21. According to reports, in 2020, online searches for chin enhancement increased by 185%, reinforcing the emerging patient need for a product like Restylane Defyne. The company stated in a press release that Restylane Defyne is the first and only chin filler to demonstrate results across a wide range of participants, including those with all skin types, male subjects and subjects over the age of 52.
Restylane Defyne is a hyaluronic acid dermal filler that was first approved in 2016 by the FDA for mid-to-deep injection into the facial tissue for the correction of moderate to severe deep facial wrinkles and folds, such as nasolabial folds, in subjects over age 21.
“My patients often come to me asking about new treatment options to continue looking their best. Many are surprised when I explain the impact of chin augmentation and how balancing the lower face is key to helping achieve total facial attractiveness,” said Anne Chapas, MD, a board-certified dermatologist and dermatologic surgeon in New York and an investigator in clinical trials of Restylane Defyne for chin. “The lower part of the face is constantly in motion, so it is important for patients to have the option of a filler like Restylane Defyne that is scientifically developed to adapt to their facial expressions.”
In addition, the company says that Restylane Defyne is the only FDA-approved filler designed for use in the chin that is produced using Galderma’s manufacturing process, XpresHAn Technology, globally referred to as the Optimal Balance Technology, which is designed to create a smooth, injectable gel that integrates into the skin for natural, dynamic movement.According to the manufacturer, treatment with Restylane Defyne in the lower face, using XpresHAn Technology, has shown to produce highly satisfactory natural looking results.
“This marks Galderma’s eighth FDA aesthetics approval in 5 years, illustrating our long-term commitment to advancing aesthetics through new innovation,” said Alisa Lask, general manager and vice president of the U.S. Aesthetics Business at Galderma. “The chin is the foundational anchor of the face that brings the rest of your features into balance. Consumers can now address the chin with a non-surgical, safe option from a brand that uses cutting-edge XpresHAn Technology to shape and produce long-lasting results.”
Results of a pivotal Phase 3 clinical trial showed that 74% of the patients experienced significantly improved chin projection for up to 1 year as measured by the Galderma Chin Retrusion Scale (GCRS), and 86% of patients, when asked at 12 weeks. Positive aesthetic outcomes following treatment were demonstrated through high levels of subject satisfaction in FACE-Q, and Global Aesthetic Improvement Scale (GAIS) questionnaires.